Sienna Biopharmaceuticals (Sienna Biopharmaceuticals) Total Current Assets : $19.73 Mil (As of Sep. 2019)

View and export this data going back to 2017. Start your Free Trial

What is Sienna Biopharmaceuticals Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Sienna Biopharmaceuticals's total current assets for the quarter that ended in Sep. 2019 was $19.73 Mil.

Sienna Biopharmaceuticals Total Current Assets Historical Data

The historical data trend for Sienna Biopharmaceuticals's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sienna Biopharmaceuticals Total Current Assets Chart

Sienna Biopharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Total Current Assets

5.64

10.52

77.35

50.41

Sienna Biopharmaceuticals Quarterly Data
	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
Total Current Assets	Get a 7-Day Free Trial											67.06	50.41	58.67	50.62	19.73

Sienna Biopharmaceuticals Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Sienna Biopharmaceuticals's Total Current Assets for the fiscal year that ended in Dec. 2018 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	48.526	+	0	+	0	+	1.886
	=	50.41

Sienna Biopharmaceuticals's Total Current Assets for the quarter that ended in Sep. 2019 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	11.332	+	0	+	0	+	8.399
	=	19.73

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Sienna Biopharmaceuticals (OTCPK:SNNAQ) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Sienna Biopharmaceuticals's Liquidation Value for the quarter that ended in Sep. 2019 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	11.332	-	20.391	+	0.75 * 0	+	0.5 * 0
=	-9.06

Sienna Biopharmaceuticals Total Current Assets Related Terms

Thank you for viewing the detailed overview of Sienna Biopharmaceuticals's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Sienna Biopharmaceuticals (Sienna Biopharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sienna Biopharmaceuticals Inc (OTCPK:SNNAQ) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

30699 Russell Ranch Road, Suite 140, Westlake Village, CA, USA, 91362

Website

http://www.SiennaBio.com

Sienna Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on bringing innovations in biotechnology to the discovery, development, and commercialization of first-in-class, targeted, topical products in medical dermatology and aesthetics. The objective is to develop multi-asset pipeline of topical therapies that enhance the health, appearance, and quality of life of dermatology patients. The product portfolio includes SNA-120, SNA-125, and SNA-001.

Executives

Alexander Azoy	officer: Chief Financial Officer	30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Timothy K. Andrews	officer: General Counsel & Secretary	30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Iii Frederick Beddingfield	director, officer: President & CEO	C/O KYTHERA BIOPHARMACEUTICALS, INC. 27200 WEST AGOURA ROAD, SUITE 200 CALABASAS CA 91301
Paul F. Lizzul	officer: Chief Medical Officer	30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Diane Stroehmann	officer: See Remarks	30699 RUSSELL RANCH ROAD SUITE 140 WESTLAKE VILLAGE CA 91362
Dennis M Fenton	director
Todd Harris	director	30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Kristina Burow	director, 10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Robert J More	director	680 S CACHE STREET, SUITE 100, BOX 10820, JACKSON WY 83001
James M. Hindman	director	2525 DUPONT DRIVE, IRVINE CA 92612
Keith R Leonard	director	ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Arch Venture Partners Viii, L.p.	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Fund Viii Overage, L.p.	10 percent owner	C/O ARCH VENTURE PARTNERS VIII, LLC, 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Fund X Overage, L.p.	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners X Overage, L.p.	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631